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BrdU = bromodeoxyuridine; Col 1 = collagen type 1; ECM = extracellular matrix; EGF = epidermal growth factor; ER = estrogen receptor; FCM =
fibroblast-conditioned medium; FN = fibronectin; HGF = hepatocyte growth factor; IGF-1 = insulin-like growth factor I; LM = laminin; PBS = phos-
phate-buffered saline; PR = progesterone receptor; R5020 = promegestone.
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Introduction
Mammary gland growth and development are mediated
through the complex interactions of steroid hormones,
polypeptide hormones, growth stimulatory factors and
growth inhibitory factors. Normal development and func-
tion of the mammary gland are also dependent upon
complex interactions between epithelial cells and stromal
cells [1,2]. Stromal cells can regulate the epithelium by the
production of soluble growth stimulatory and/or inhibitory
factors; and components of the extracellular matrix such
as collagens, fibronectin and laminin can also act as sig-
naling molecules for epithelial cells, via specific integrins
on epithelial cells. Epithelial cells also secrete factors that
influence proliferation and function of adjacent epithelial
and stromal cells (Fig.1).
Although there have been numerous studies of signalling
mediated by the extracellular matrix and integrin in normal
mammary gland and breast cancer cell lines, none has
addressed the role of stroma in mediating and modulating
steroid hormone action. There is increasing evidence that
a number of responses to estrogen and/or progesterone
in the mammary gland may be mediated indirectly through
paracrine effects. This review focuses on recent studies
from our laboratory addressing interactions between
epithelial cells and stromal cells and between steroid hor-
mones and growth factors in the normal murine mammary
gland and in human breast cancer cells.
Steroid hormones and mammary gland
development
Estrogen and progesterone are required for proliferation
and morphogenesis of the normal mammary gland. Estro-
gen drives ductal development during puberty, whereas
estrogen+progesterone mediate the proliferative and
morphological changes of ductal side-branching and alve-
ologenesis that occur at sexual maturity and during preg-
nancy [1,2]. Progesterone is also mitogenic in the
premenopausal and postmenopausal human breast [3].
The greater risk of breast cancer in postmenopausal
women receiving combined estrogen plus progestin
hormone replacement therapy than in those receiving
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Abstract
Mammary epithelial cells comprise the functional component of the normal gland and are the major
target for carcinogenesis in mammary cancer. However, the stromal compartment of the normal gland
and of tumors plays an important role in directing proliferative and functional changes in the epithelium.
In vivo and in vitro studies of the murine mammary gland have provided insights into novel stroma-
dependent mechanisms by which estrogen and progesterone action in the epithelium can be
modulated by hepatocyte growth factor (HGF) and the extracellular matrix proteins, collagen type I,
fibronectin and laminin. In vitro and in vivo studies of estrogen receptor positive, estrogen-responsive
human breast cancer cells have also demonstrated that estrogen responsiveness of tumor cells can
also be modulated by extracellular matrix proteins, collagen type I and laminin.
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estrogen alone indicates a significant role for proges-
terone in mammary carcinogenesis [4].
Mammary stroma and estrogen-induced
proliferation and morphogenesis in the
epithelium
Estrogen receptors (ERs) are expressed in both epithelial
and stromal cells [5], and certain estrogenic effects in the
epithelium are modulated by mammary stroma both in vivo
and in vitro (review [1]). Studies in both rodent and human
mammary tissues have shown that markers of proliferation
such as Ki67, proliferating-cell nuclear antigen or BrdU
incorporation and ERs are rarely colocalized in the same
epithelial cells, suggesting that the proliferating epithelial
cells are not the ER+ cells [6,7]. Studies of mice from
which the ERα gene has been deleted indicate that the
presence of ER+ stroma is needed for an estrogen-
induced proliferative response of the epithelium [8].
To investigate the mechanism of the effects of estrogen-
dependent stroma in the mammary gland, we have studied
murine mammary epithelium in vitro using a minimally sup-
plemented, serum-free, three-dimensional collagen-gel
primary cell-culture system. We found that ER+ mammary
fibroblasts can mediate estrogen-induced proliferation in
mammary epithelial cells via stroma-derived hepatocyte
growth factor (HGF) [9]. Conditioned medium from
mammary fibroblasts (FCM) or coculture with mammary
fibroblasts causes increased epithelial-cell proliferation
and induces a tubular/ductal morphology (Fig.2a,b). HGF
was identified as the mediator of this effect, since the pro-
liferative and morphogenic activity in FCM is completely
abolished by neutralizing antibody to HGF but not by neu-
tralizing antibodies to epidermal growth factor (EGF) or
insulin-like growth factor 1 (IGF-1) [10]. Although HGF is
constitutively produced by mammary fibroblasts in vitro
under our culture conditions, its production is increased
by treatment of such cultures with estrogen. In contrast,
direct addition of estrogen to epithelial cultures produces
neither a proliferative nor a morphological response,
despite the presence of ER (Fig.2c). This suggests that
in vivo the proliferative effects of estrogen may be medi-
ated indirectly by HGF. It is also possible that in vivo regu-
lation of HGF production is more complex than observed
in vitro and may be controlled by both inhibitory and stimu-
latory factors. Because ERα and  β are both present in
mammary fibroblasts under these culture conditions, we
do not yet know which ER isoform mediates HGF regula-
tion. EGF or IGF-1 also effectively induces proliferation in
cultured epithelial cells (Fig.2d), but these growth factors
each produce a different morphology from that produced
by FCM or HGF. Whether a similar mechanism is opera-
tive in the human breast is not known; however, HGF is
produced in normal breast stroma [11].
Mammary stroma and progestin-induced
proliferation and morphogenesis in the
epithelium
That expression of progesterone and of progesterone
receptor (PR) in the epithelium is required to induce ductal
side-branching and alveologenesis in the adult mammary
gland and during pregnancy has been confirmed by the
absence of alveologenesis and lactational function in the
mouse from which the PR gene has been deleted [12,13].
Although PRs are present in epithelial cells at puberty, the
pubertal mammary gland is much less responsive than the
adult mammary gland to the proliferative and alveologenic
actions of progesterone [2]. Responsiveness to progestin
can be precociously induced in pubertal epithelial cells
surgically recombined with adult mammary stroma [14].
Thus, mammary stroma also influences responsiveness of
the epithelium to progestin.
Using the culture system described above, we investi-
gated stromal influences on progestin-dependent prolifer-
ation and alveologenesis in adult murine mammary
epithelium [10]. We find that the synthetic progestin
R5020 (promegestone) fails to induce proliferation of
epithelial cells when added either by itself or with estrogen
(Fig.3a). However, when progestin is added with FCM, it
increases the proliferation of epithelial cells to more than
that seen in conditioned medium alone (Fig.3b). The
active growth factor in conditioned media with which
R5020 interacts is HGF (Fig.3c,d).
Of particular interest is the unique morphology observed in
HGF+R5020-treated cultures. HGF on its own induces
extensive formation of duct-like tubular structures (see
Fig.2b), whereas R5020 on its own produces cyst-like
structures containing a single lumen (see Fig. 3c). Treat-
ment with HGF+R5020 reduces tubule formation and
induces the formation of multiluminal alveolar-like struc-
tures, similar to that observed in response to progesterone
Figure 1
Model of epithelial-cell–stromal-cell interactions. ECM, extracellular
matrix; ER, estrogen receptor; PR, progesterone receptor.210
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treatment of adult mammary gland in vivo (Fig.3d). The
proliferative and morphological responses to R5020
(lumen formation, alveologenesis) are progestin-specific
and can be inhibited by the antiprogestin RU486 (Fig.3d).
Analysis of apoptosis in progestin-treated organoids shows
that apoptotic cells are localized within the center of the
epithelial organoids. This is in contrast to control-treated
organoids, in which apoptotic cells are located on the outer
periphery of the organoid [10]. This topographically local-
ized apoptotic effect of R5020 within the organoid sug-
gests that this may be the mechanism by which progestins
cause lumen formation and that progestins may also play a
key role in lumen formation in the mammary gland.
Treatment with progestin and EGF or with progestin and
IGF-1 produces no increased proliferation or alveologenic
response [10]. Treatment with R5020+EGF does not
increase proliferation above EGF alone. The potent mito-
genic activity of IGF-1 by itself is halved by the addition of
R5020 [10]. These results indicate that progesterone
interacts differently with HGF, EGF and IGF-1. Thus, the
effects of progesterone at different stages of mammary
gland development may be modulated by differential
expression of specific growth factors.
In human and mouse mammary glands, HGF is expressed
only in mammary fibroblasts, and the HGF receptor, Met, is
Figure 2
Response of murine mammary epithelial cells to co-culture with mammary fibroblasts and to fibroblast conditioned medium. (a) Proliferation of
epithelial cells cocultured with mammary fibroblasts or in the presence of conditioned medium obtained from mammary fibroblasts. Murine mammary
epithelial cells were suspended in collagen type I gels and cultured alone in basal medium (EPI), over mammary fibroblasts in basal medium
(CO-CULT), or in the presence of fibroblast-conditioned medium (FCM). 3H-thymidine incorporation into DNA was assayed after 3 days of culture.
*P = 0.01 that proliferation is greater under coculture condition and in the presence of FCM. (b) Phase-contrast photomicrographs (i–iv) and
histological sections (v,vi) showing the tubular/ductal structure of organoids of epithelial cells in collagen-gel cell culture. Mammary epithelial cells
were cultured alone in basal medium, cocultured with mammary fibroblasts in basal medium (CO-CULTURE), cultured alone in the presence of
fibroblast-conditioned medium (FCM), or cultured in the presence of 50 ng/ml HGF (HGF) for 3 days. ×100 (i–iv), ×400 (v,vi). (c) Effect of FCM and
estrogen on proliferation of epithelial cells. Mammary epithelial cells were cultured alone in collagen type I in basal medium, in the presence of 20 nM
E2, in FCM, or in FCM obtained from fibroblasts cultured in the presence of 20 nM estradiol (E2FCM); to block any effect of estradiol in the epithelial
cells, 200 nM of the antiestrogen, ICI 182,780, was added to epithelial cells at the same time as E2FCM was added. In the presence of BM (i) only
solid spheres were observed. Coculture with fibroblasts (ii), or treatment with FCM (iii), or HGF (iv) produced organoids with a tubulo/ductal
morphology. Organoids cultured in the presence of EGF or IGF-1 (d) produced a flattened, sheet-like morphology with few or no tubules. *P = 0.01
that proliferation in the presence of FCM was greater than in basal medium or in the presence of E2. **P = 0.05 that proliferation in the presence of
E2FCM was greater than with all other treatments. (d) Morphological response of mammary epithelial cells to EGF (50 ng/ml) or IGF-1 (100 ng/ml).
Phase-contrast photomicrographs of epithelial cells were taken on day 3; ×100. BM, basal medium; cpm, counts per minute; E2, 17β-estradiol; 
EGF, epidermal growth factor; FCM, fibroblast-conditioned medium; HGF, hepatocyte growth factor; IGF-I, insulin-like growth factor I; Tdr, thymidine.211
expressed only in epithelial cells [11,15]. In mouse
mammary gland, HGF expression starts to rise at midpu-
berty (6 weeks of age) and is maximally expressed at sexual
maturity (12 weeks of age), when the mammary gland is
poised for progesterone-induced ductal side-branching
and alveolar development. HGF is also present during
pregnancy, when maximal alveolar development occurs,
and declines to prepubertal levels during lactation. Thus,
the in vivo pattern of HGF expression is compatible with
effects on ductal elongation and alveologenesis. To test
the effects of endogenous HGF on ductal development
and alveologenesis in vivo, neutralizing antibody to HGF
was implanted directly into the mammary glands of puber-
tal or adult mice. In pubertal mice with intact ovaries, HGF
antibody inhibits ductal elongation (Fig.4a,b). Adult mice
with intact ovaries were given two implanted Elvax pellets
side by side, one containing estrogen+R5020, the other
containing anti-HGF antibody (Fig.4e). Alternatively, an
Elvax pellet containing anti-HGF antibody was implanted in
the right inguinal mammary gland and a control Elvax pellet
in the contralateral gland, and the mice were then given
daily injections of estrogen+progesterone for 6 days
(Fig.4c,d). In both cases the ductal side-branching induced
in response to treatment with estrogen plus progestin was
inhibited by anti-HGF antibody. Thus, in the adult gland,
HGF appears to play important roles in both ductal elonga-
tion during puberty and ductal side-branching, the initial
stage in alveolar development, in the adult gland.
Extracellular matrix and integrin-mediated
hormone interactions in normal mouse
mammary gland
Mammary stroma can also influence the behavior of
epithelial cells by altering the composition of extracellular
Available online http://breast-cancer-research.com/content/5/4/208
Figure 3
Effect of R5020 plus HGF on proliferation of epithelial cells. Murine mammary epithelial cells were suspended in collagen type I gels and cultured
in (a) HGF alone (HGF, 50 ng/ml) or with HGF in combination with E2 (10 nM), R5020 (20 nM) or E2+R5020 (10 nM+20 nM) or (b) in FCM with or
without R5020 or E2+R5020. 3H-thymidine incorporation into DNA was assayed after 3 days of culture. The data are expressed for suspensions in
basal medium as 3H-thymidine incorporated per well and for HGF- and FCM-treated groups as fold increase over basal-medium control. *P = 0.05
that proliferation is greater in HGF+R5020 group than in HGF or HGF+E2. ** P = 0.01 that the fold increase in proliferation in suspensions in
HGF+ E2+R5020 and FCM+ E2+R5020 is greater than in all other groups within the same experiment. (c) Phase-contrast photomicrographs of
epithelial cell organoid morphology in collagen gel cell culture after 3 days in basal medium containing R5020, RU486, HGF, R5020+HGF,
RU486+R5020, or RU486+R5020+HGF. ×100. Note appearance of lumens (L) and alveolar buds (AB) in R5020 and R5020+HGF-treated
cultures, respectively, and long tubules (T) in HGF and RU486 +R5020 +HGF-treated cultures. No lumen or alveolar bud formation was observed
in the presence of RU486. (d) Histological sections of three separate alveolar-like organoids obtained from cultures treated with HGF+R5020;
note presence of multiple lumens (L) within these structures. AB, alveolar bud; E2, 17β-estradiol; FCM = fibroblast-conditioned medium; 
HGF = hepatocyte growth factor; T, tubule.212
matrix (ECM), which affects signaling pathways mediated
by integrins. In vitro studies of the effects of ECM proteins
in mammary epithelial monolayer cultures derived from
adult mammary gland have been reviewed recently [16].
Interactions between steroid hormones and growth factor
and between two growth factors are influenced by ECM
composition. Collagen type I (Col I) and fibronectin (FN)
and, to a lesser extent, laminin (LM) promote an
EGF+IGF-1 synergistic effect on proliferation. No syner-
gistic, additive or inhibitory effects of progestin or estro-
gen with growth factors are observed on Col I or FN.
However, on LM, progestin reduces the proliferative
response to growth factors [17]. This suggests that sig-
naling pathways specific to ECM integrin can alter interac-
tions between steroid hormones and growth factors.
We have also investigated the hormonal regulation and
functional role of ECM proteins and integrins in vivo
during mammary gland development [18]. Of Col I, LM
and FN, only FN levels change appreciably, increasing
threefold between puberty and sexual maturity and remain-
ing high during pregnancy and lactation. FN levels are hor-
monally regulated by estrogen and progesterone. The
FN-specific integrin α5β1 is also developmentally and hor-
monally regulated. It increases twofold between puberty
and sexual maturity but decreases during late pregnancy
and lactation. The α5β1 integrin level is also decreased by
ovariectomy and restored by treatment with
estrogen+progesterone. The high levels of α5β1 expres-
sion during periods of steroid-induced proliferation indi-
cate that FN signaling may be required for
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Figure 4
Representative photomicrographs of mammary-gland whole mounts after implantation with neutralizing antibody to HGF. Immature, 5-week-old
(a,b) or adult, 12- week-old (c,d) female mice were given implants of Elvax pellets containing anti-HGF antibody (HGF AB) (4 µg/implant) in the
right inguinal mammary gland (b,d) or a control (C) Elvax pellet containing normal serum in the contralateral left inguinal gland (a,c) and were then
given daily injections of estrogen + progesterone for 6 days. In addition, adult 12-week-old female mice were given two Elvax pellets implanted side
by side, one containing estrogen+R5020, the other containing HGF AB (e). In all cases, whole mounts were prepared 7 days later. Note reduced
size of endbuds (indicated by arrows) in the immature gland with implanted HGF AB (b) in comparison with the control (C)-implanted gland in (a)
(arrowheads). Note the presence of side-branches in control (C)-implanted adult gland (c) (arrowheads) and their absence in glands with HGF AB
implants (d) (arrows). Note the presence of side-branches near the estrogen+R5020 implant (indicated by arrowheads) and their absence near the
antibody implant (e) (arrows). C, control; E, estrogen; HGF, hepatocyte growth factor; HGF AB, anti-HGF antibody.213
hormone-dependent proliferation. Furthermore, the spe-
cific temporal pattern of integrin, and growth factor
expression relative to the temporal patterns of estrogen-
directed vs progesterone-directed morphogenesis,
suggest that integrin-mediated signaling may interact with
growth factor and steroid hormone signaling pathways to
modulate their effects on proliferation and morphogenesis.
Laminin and estrogen-dependent growth in
human breast cancer cells in vitro and in vivo
In breast cancer, LMs have been shown to play an impor-
tant role in progression and metastasis. Several groups
have demonstrated that expression of the α6 subunit of
the LM-specific integrin is associated with breast cancer
progression, aggressive disease and substantially
reduced survival [19–21]. We have shown that LM modu-
lates estrogen action in ER+ breast cancer cells in vitro
[22]. Estrogen induces significant proliferation in both ER+
MCF-7 and T47D cancer cells when cultured on Col I or
FN, but not on LM. Even though ER levels and ER binding
are not altered on LM, estrogen response element activa-
tion by estrogen is significantly decreased on LM. Interest-
ingly, inhibition of proliferation by LM is specific to
estrogen, since IGF-1 and EGF are able to induce prolifer-
ation of MCF-7 cells similarly on LM, Col I and FN, sug-
gesting that proliferation of these cells is mediated
primarily by growth factors.
In vivo studies have been carried out to determine the
effect of LM on MCF-7-derived solid tumors. MCF-7 cells
were implanted subcutaneously with no ECM (PBS
control), or with soluble Col I or LM, in ovariectomized
nude mice supplemented with estrogen. The LM and Col I
groups were subsequently divided in half and either con-
tinued to receive estrogen alone or received
estrogen+antiestrogen (ICI 182,780). Tumor growth in the
presence of estrogen is slightly higher in Col-I-treated
tumors than in PBS controls but is significantly lower in
animals with LM-treated tumors (Fig.5). Importantly, treat-
ment with antiestrogen causes regression of tumors
treated with Col I but does not affect those treated with
LM (Fig.5b). Thus, LM inhibits antiestrogen responsive-
ness as well as estrogen responsiveness in these ER+
tumor cells. This is especially relevant because antiestro-
gen resistance occurs in 30% of ER+ primary tumors and
is also associated, through undefined mechanisms, with
breast cancer progression. Our in vivo findings with
LM-treated MCF-7 cells suggest that high levels of LM in
the tumor ECM might be predictive of ER+ primary tumors
that will not respond to antiestrogen therapy.
Laminin and Col I can initiate cell signaling via the α2 inte-
grin subunit. However, the α6 subunit, which exists as an a
or b isoform, confers specificity to LM integrin signaling.
Since MCF-7 cells retain estrogen responsiveness on
Col I, we reasoned that LM signaling through α6 might be
responsible for loss of estrogen responsiveness on LM. In
addition, increased expression of the α6 integrin subunit
has been associated with breast cancer progression. To
investigate whether α6 expression influenced estrogen-
responsiveness in breast cancer cells, we stably trans-
fected MCF-7 cells with α6a and α6b expressing plasmid
constitutively activated by a cytomegalovirus promoter. In
contrast to wild-type MCF-7 cells, which proliferate in
response to estrogen on Col I (Fig.6a), we found that
neither the α6a nor α6b transfectants proliferate in
response to estrogen on Col I (Fig.6b). IGF-1-induced
proliferation was significant and was similar to that in wild-
type, non-transfected MCF-7 cells; however, there is no
additive effect of estrogen+IGF-1 in transfected cells
comparable to that seen in wild-type MCF-7 cells. This
suggests that LM binding affects the pathway whereby
estrogen and IGF-1 signaling converge to promote prolif-
eration. Collectively, these data indicate that LM and the
α6 integrin subunit may be key regulatory components of
estrogen-responsiveness and antiestrogen resistance in
Available online http://breast-cancer-research.com/content/5/4/208
Figure 5
Growth of MCF-7 cells as tumors in nude mice. MCF-7 cells were mixed with PBS (control) (a) or Col I (a,b) or LM (b) and implanted
subcutaneously in ovariectomized nude mice supplemented with estradiol. (b) Mice were subsequently divided into two groups, which received
either estradiol (Col 1, LM) or estradiol + antiestrogen (ICI 182,780) (Col + ICI, LM + ICI). Col 1, collagen type 1; LM, laminin; ICI, ICI 182,780.214
certain breast cancer cells, independent of ER expression.
The mechanism by which LM induces loss of estrogen
responsiveness is under active investigation. We hypothe-
size that the lack of estrogen-responsiveness of MCF-7
cells adhered to LM is due to LM-specific α6
receptor/integrin-mediated signaling. The specific down-
stream mediators of the intracellular signaling pathway
activated by LM integrin binding do not provide the appro-
priate substrate(s) required for estrogen-induced prolifera-
tion. Thus, these tumor cells do not respond to estrogen
to proliferate, and consequently their growth is not inhib-
ited by endocrine therapy.
Conclusions
In vivo and in vitro studies of interactions between epithe-
lial cells and stromal cells in normal murine mammary
gland have provided insights into the underlying mecha-
nisms of these interactions to mediate and modulate
estrogen- and progesterone-dependent proliferation and
morphogenesis. These studies have been extended to
potential interactions between human breast cancer cells
and surrounding stroma and have led to intriguing findings
of ECM-mediated modulation of estrogen-responsiveness
in human breast cancer cells in vitro and in vivo. Further
studies are needed to elucidate the mechanisms underly-
ing stroma-mediated influences in breast cancer and may
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